Hereditary Testing Market is anticipated to growth over the forecast period
Hereditary Testing Industry Overview
The global hereditary testing market size was valued at USD 5.8 billion in 2019 and is projected to register at a CAGR of 6.3% during the forecast period. The expanding reproductive genetic health space is one of the key market drivers. Key players, such as Natera, have reported a continuous increase in test volumes in women’s health genetic testing for inherited conditions. This reflects the growing acceptance of hereditary tests among the population, thereby accelerating revenue growth.
Furthermore, a consistent rise in demand for newborn screening has led to an increase in sales of DNA testing kits. For instance, in November 2019, the Division of Consolidated Laboratory Services (DCLS) of the Virginia Department of General Services screened 7,868 newborns for nearly 31 hereditary and metabolic disorders. Increasing penetration of newborn screening across the globe is further aiding in revenue growth.
Reforms in genetic testing guidelines have led to inclusion of multigene panel testing for hereditary cancer into clinical practice. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers offers information on some of the cancer risk factors and management recommendations for single and multiple gene panels.
Gather more insights about the market drivers, restrains and growth of the Global Hereditary Testing market
Gradual developments in the distribution model is likely to benefit the genetic testing market. Technology providers are playing a crucial role in market growth by improving their distribution service and increasing the efficiency of technology. Companies are using a cloud-based distribution model to make bioinformatics technology available for use by other laboratories. As of March 2019, around 14 licensees were using Constellation software commercially for the marketing of Non-invasive Prenatal Testing (NIPT) products.
Although these hereditary tests have huge advantages over conventional tests, several industry experts cited the cost and security concerns faced by consumers pertaining to the test. Moreover, the lack of effective regulation of the tests is another key area that demands focused efforts. Despite these challenges, the genetic testing market is constantly expanding owing to the advantages of these innovative tests along with improved healthcare outcomes.
Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.
- Bioinformatics Services Market - The global bioinformatics services market was valued at USD 1.32 billion in 2015. The industry is anticipated to be driven by increasing government initiatives and funding for genomics oriented R&D, growing application of the technology in drug discovery as well as biomarker development processes.
- Non Invasive Prenatal Testing Market - The global non invasive prenatal testing market size was valued at USD 2.83 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 10.9% from 2021 to 2028. The increasing incidence of chromosomal abnormalities coupled with growing product usage in new applications is driving the organic revenue growth in the market.
Hereditary Testing Market Segmentation
Grand View Research has segmented the global hereditary testing market based on disease type, and region:
- Disease Type Outlook (Revenue, USD Million, 2015 - 2026)
- Hereditary Cancer Testing
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Ovarian Cancer
- Prostate Cancer
- Stomach/Gastric Cancer
- Melanoma
- Sarcoma
- Uterine Cancer
- Pancreatic Cancer
- Others
- Hereditary Non-cancer Testing
- Genetic Tests
- Cardiac Diseases
- Rare Diseases
- Other Diseases
- Newborn Genetic Screening
- Preimplantation Genetic Diagnosis & Screening
- Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
- Genetic Tests
- Regional Outlook (Revenue, USD Million, 2015 - 2026)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
- Hereditary Cancer Testing
Market Share Insights
- September 2021: MedGenome Labs launched its direct-to-consumer category under the brand name Genessense which will offer specialized, evidence-based genetic screening tests that can be ordered online through the Genessense website or via e-commerce platforms in the future.
- April 2019: Ambry Genetics and Intalere Teams partnered. As a result of this partnership, the firm was able to have greater access to healthcare facilities with genetic research in order to better treat patients with elevated cancer risks
Key Companies profiled:
Some prominent players in the global hereditary testing market include
- Myriad Genetics, Inc.
- Invitae Corporation
- Illumina, Inc.
- Natera, Inc.
- Laboratory Corporation of America Holdings
- Hoffmann-La Roche Ltd
- Quest Diagnostics Incorporated
- CooperSurgical, Inc.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
Order a free sample PDF of the Hereditary Testing Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Comments
Post a Comment